Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., Blank, C., Cranmer, L.D., Robert, C., Pavlick, A.C., Gonzalez, R., Hodi, F.S., Ascierto, P.A., Salama, A., Margolin, K.A.,Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw379.02
Date:
October, 2016
File:
PDF, 45 KB
english, 2016